IRTC IRhythm Technologies Inc.

iRhythm Technologies Announces the Appointment of Renee Budig to its Board of Directors

iRhythm Technologies Announces the Appointment of Renee Budig to its Board of Directors

SAN FRANCISCO, April 23, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the appointment of Renee Budig to its Board of Directors effective April 23, 2020. Ms. Budig was appointed as a Class II director and will also serve on the Audit Committee. 

“On behalf of the iRhythm team, I am delighted to welcome Renee to our Board of Directors,” said Kevin King, CEO. “Renee has a very strong finance and operations background as a leader and advisor to a number of successful technology companies. Renee will fill a key role in bringing additional experience and perspectives to iRhythm. We are looking forward to Renee’s contributions to guide iRhythm to continued success and help us scale our operations.”

On her appointment, Ms. Budig commented, “I am thrilled to join the Board of iRhythm, a recognized leader in the digital health space. iRhythm has shown a track record of innovation and is changing the status quo in cardiac monitoring. I am looking forward to contributing my expertise and helping iRhythm continue to grow and scale their digital health platform.”

Following the appointment of Ms. Budig, iRhythm’s Board is comprised of eight directors.

About Renee Budig

Ms. Budig has served as a member of the Board of Directors and as Chair of the Audit Committee of Chegg, Inc. since November 2015. Since September 2012, Ms. Budig has served as the Executive Vice President and Chief Financial Officer of CBS Interactive, a division of ViacomCBS, the world’s largest publisher of premium digital content and a perennial top 10 Internet company. Previously, Ms. Budig served as Chief Financial Officer of Hightail, Inc. (formerly branded YouSendIt and acquired by OpenText), a cloud service that allowed users to send, receive, digitally sign and synchronize files. Prior, Ms. Budig was the Vice President of Finance at Netflix, Inc. and the Vice President of Finance for Veritas Software. Ms. Budig holds a B.S. in Business Administration from the University of California, Berkeley.

                                                              

About iRhythm Technologies, Inc. 

iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Investor Relations Contact:

Lynn Pieper Lewis or Leigh Salvo

(415) 937-5404



                   Media Contact

Saige Smith

(262) 289-7065

   



EN
23/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 5,000 shares at 175.000USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial ...

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhythm’s Zio long-term continuous monitoring (LTCM) device and service could improve diagnosis of atrial fibrillation (AFib) in 5040 participants in the United ...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)Morgan Stanley Global Healthcare Conference 2025 on Tuesday, September 9, 2025, at 2:35 p.m. Eastern Time (11:35 a...

 PRESS RELEASE

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm...

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service’s value across patient populations and payer segments. SAN FRANCISCO, Aug....

 PRESS RELEASE

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution f...

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a digital health leader focused on creating trusted solut...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch